- CEO
- Yu Fen Liu
- Full Time Employees
- 47
- Sector
- Consumer non-durables
- Industry
- Food: major diversified
- Address
- No.52, Gongye 3rd Road Tainan TQ Taiwan 709
- IPO Date
- Sep 18, 2018
- Business
- DaBomb Protein Biotech Corp. (6578.TWO), headquartered in Tainan City, Taiwan, and founded in 2001, develops and manufactures plant-based proteins, antibiotic alternatives, and related biotech products for the animal health, aquaculture, livestock, pet care, and agricultural sectors. The company produces core offerings including hydrolyzed soya peptides such as DaBomb-P (Aqua) for aquaculture feed and DaBomb-P (Livestock) for animal nutrition; antibiotic alternatives like DBT-100 HT, DBT-100 LS, and postbiotic-based ProbioSyntec solutions leveraging innovative fermentation technology; functional peptides and natural L-lactate as food additives; pet care items comprising Liqui-TIDE bandages; and plant biostimulants like DaBomb Ti featuring fermented peptides and 18 amino acids for crops, fruit trees, vegetables, and turf. It operates factories in Taiwan, including sites in Tainan and Pingtung Agricultural Biotechnology Park, and in Zhangzhou, Fujian, China, exporting primarily to Southeast Asia, Northeast Asia, and other international markets with an annual production capacity exceeding 40,000 tons. Recent developments include its 2023 renaming from DaBomb Protein Corp. to DaBomb Protein Biotech Corp., attainment of FAMI-QS Bioprocess and Mixing certifications, ongoing ProbioSyntec development since 2020, a 2024 CDMO partnership with a US feed enzyme company for protease production, and groundbreaking in late 2024 on a new Tainan fermentation facility set for 2025 operations to expand capacities.